title: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach.
abstract: BACKGROUND
  Chemotherapy represents the standard treatment for patients with metastatic stomach cancer. Conflicting results have been published regarding the activity of paclitaxel in this setting. Therefore, we developed a phase II study to evaluate an outpatient 3 h infusion of paclitaxel.
  
  
  METHODS
  Patients with chemonaive metastatic stomach cancer received paclitaxel 210 mg/m(2) every 3 weeks. Patients with esophageal cancer were not eligible.
  
  
  RESULTS
  Twenty-one patients were enrolled. The median age was 55.5 years (range 37-81 years). Two partial responses were observed among the 18 patients evaluable for response and toxicity (response rate 11%, 95% CI: 2-33%). The median time to progression was 10.5 weeks and median survival 23 weeks. There was only one episode of grade IV neutropenia and no episodes of grade 3-4 non-hematological toxicity were observed.
  
  
  CONCLUSIONS
  Paclitaxel exhibited minimal activity in this patient population.
authors.affiliation: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90089-9173, USA. aagarcia@hsc.usc.edu
authors.forename: A A
authors.initials: AA
authors.lastname: Garcia
authors.forename: C G
authors.initials: CG
authors.lastname: Leichman
authors.forename: H J
authors.initials: HJ
authors.lastname: Lenz
authors.forename: J
authors.initials: J
authors.lastname: Baranda
authors.forename: R
authors.initials: R
authors.lastname: Lujan
authors.forename: Y
authors.initials: Y
authors.lastname: Casagrande
authors.forename: L
authors.initials: L
authors.lastname: Leichman
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel